Dream2Heal: An Adaptive Stepped-care Intervention for Chinese Cancer Survivors With Mild-to-moderate Insomnia
Launched by THE UNIVERSITY OF HONG KONG · Feb 2, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The Dream2Heal clinical trial is looking at a new program to help improve sleep quality for Chinese cancer survivors who are dealing with mild to moderate sleep problems. This study is specifically for patients who speak Cantonese or Mandarin and have recently finished treatment for breast, colorectal, or gynecological cancer. To be eligible, participants should have a sleep quality score that shows they are experiencing some sleep disturbances, but not severe problems.
If you or someone you know fits these criteria, you could be part of this important study. Participants will receive support aimed at improving their sleep through a step-by-step approach. This means that the program can adapt to what works best for each individual. The trial is currently recruiting and aims to gather valuable information about how effective this intervention is for enhancing sleep quality in cancer survivors. Joining the trial may also provide access to helpful resources and support during the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cantonese- or Mandarin-speaking Chinese patients diagnosed with curable breast, colorectal, or gynaecological cancer
- • Completed treatment (except endocrine therapy) within two years
- • Presenting with Pittsburgh Sleep Quality Index (PSQI) score of 6 to 11 indicating mild-to-moderate sleep disturbance
- Exclusion Criteria:
- • Diagnosis of metastatic cancer
- • Current diagnosis of psychiatric disorder
- • Current diagnosis of another sleep disorder,
- • Have received psychological treatment specifically for sleep disturbance
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Wendy Wing Tak Lam, PhD
Principal Investigator
School of Public Health, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported